Recordati SpA (RICFY) reports a 30.5% increase in net revenue and upwardly adjusts its full-year financial targets, showcasing robust performance and strategic progress.
By Daniella Parra Recordati said it will acquire the global rights to Enjaymo, used to treat a rare blood disorder, from Sanofi. Enjaymo has been approved by the FDA, European Commission, and Japan’s ...
Some results have been hidden because they may be inaccessible to you